Opus Bio and Juno Therapeutics sign license agreement relating to CD-22 targeted cancer therapy
Client(s) Opus Bio, Inc.
Jones Day advised Opus Bio, Inc., a diversified biologics company, in connection with an exclusive patent licensing agreement with Juno Therapeutics, Inc., a U.S. biopharmaceutical company, covering a CAR-T cell product candidate targeting CD22, a protein expressed on most B cell leukemias and lymphomas. The CD22-targeted CAR T cell product candidate was developed by the National Cancer Institute (NCI) under cooperative research and development agreement (CRADA) with Opus Bio, Inc. The NCI has begun enrollment in a Phase I trial evaluating pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL) or non-Hodgkin's lymphoma (NHL).